Psoriatic Arthritis

A new trial of magnetic resonance imaging finds that analyzing scans for subclinical signs of inflammatory joint disease can help predict which psoriasis patients will go on to develop psoriatic arthritis.

A 96-week-long trial of etanercept (Enbrel) indicates durable therapeutic benefits and no serious adverse events in pediatric patients with psoriatic arthritis and other types of juvenile idiopathic arthritis.

Patients with arthritis may eventually be able to use their own "microvesicles" as treatment for their disease.

Analysis of questionnaire data has identified 5 factors that help predict which patients with chronic inflammatory rheumatic diseases such as psoriatic arthritis will abandon biologic treatment.

A recent report found there is not nearly enough scientific research being conducted on the effects of marijuana and other cannabinoids on rheumatic diseases.

Neither psoriatic arthritis (PsA) nor cutaneous psoriasis (PsC) are considered risk factors for patients undergoing total hip arthroplasty (THA).

Part of an ongoing series that takes a high-level look at the positions of the leading nominees for President when it comes to political issues potentially impacting physicians, this installment focuses on Bernie Sanders.

Part of an ongoing series that takes a high-level look at the positions of the leading nominees for President when it comes to political issues potentially impacting physicians, this installment focuses on Marco Rubio.

A new study comparing psoriatic arthritis patients who do and do not develop cardiovascular disease suggests a strong connection between arthritis that’s polyarticular at onset and diabetes and subsequent strokes and coronary events.

The FDA has granted approval for betamethasone diproprionate (Sernivo Spray/ Dr. Reddy-Promius Pharma) to treat mild-to-moderate plaque psoriasis in patients at least 18 years of age.

Psoriatic arthritis, a chronic skin condition that affects patients on physically and mentally – often impacts patients’ mobility in their daily lives. Healthcare professionals across all specialties have experience when dealing with these patients in different capacities.

Doing yoga improved rheumatoid arthritis and osteoarthritis and mood for female adults following trend of benefits associated with other conditions.

New analysis of data from longitudinal cohorts finds that psoriatic arthritis patients were more than 50% more likely than those with psoriasis but no arthritis to develop infection. It also provides further evidence that biologic medications are also a risk factor for infection.

Connective tissue disease (CTD) groups together various disorders, such as rheumatoid arthritis and lupus. A new study from the University of Chicago found that complications from these diseases are more prominent based on race.

A recent study revealed the pathogenic similarities and differences between cutaneous psoriasis and psoriatic arthritis.

Developing arthritis could increase the risk of falling into poverty, especially for female patients.

Blood analysis in patients with inflammatory rheumatic diseases such as psoriatic arthritis indicates that biologic medications do not reduce the efficacy of anti-pneumococcal polysaccharide vaccine, and that patients with such conditions may not need to be vaccinated more frequently than others.

Age matters when it comes to patients’ access to psoriasis treatment.

Biologic drug secukinumab (Cosentyx/Novartis), already FDA approved in January 2015 to treat chronic plaque psoriasis, has now been approved for two new indications: the treatment of active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

A new patient registry analysis assessed whether there were any significant differences in outcome between combination therapy and monotherapy in patients with psoriatic arthritis.

Investigators looking to compare the risks of 13 different targeted immunomodulators gathered 51 observational studies and 10 randomized controlled trials that made head-to-head comparisons. Most of the studies involved patients with rheumatoid arthritis but the underlying research also included patients with ankylosing spondylitis, inflammatory bowel diseases, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis

Graded drug challenges are considered the gold standard for evaluating patients with a low-risk history of a prior adverse drug reactions – like a mild rash or unknown reaction to penicillin as a child.

High levels of soluble biglycan (sBGN) are present in the synovial fluid of patients with severe osteoarthritis and rheumatoid arthritis. While the connection between sBGN and inflammation had been established by previous research, this study is among the first to demonstrate that higher concentrations of sBGN are present in more severe arthritis cases.

A literature review concluded that multi-faceted interventions can lead patients with psoriatic arthritis and other immune-mediated inflammatory disorders to improve their adherence to treatment regimens.

The European League Against Rheumatism (EULAR) has drawn upon 3 years of fresh research to update its guidelines for the systematic management of psoriatic arthritis for the first time since 2012.

New research on the cost of treating psoriatic arthritis indicates that, on average, the annual bill for medical care and prescription medication totals just under $20,000 per patient, but that total costs vary greatly among individual patients.

The development pipeline for psoriasis in summary.

Price increases for psoriasis have consistently outpaced the Consumer Price Index, expert says.

New research designed to measure the accuracy and validity of a trio of tools designed to assess quality of life in psoriatic arthritis patients indicates that none are comprehensive enough to be used alone and suggests that caregivers use 2 of the assessments in tandem.

Study results suggest that a treatment for psoriasis and multiple sclerosis may induce a dangerous adverse effect, particularly in women. The finding is potentially important, because while treatment with fumaric acid esters has been around for more than 40 years, it is now being used more widely in the United States, Germany, and other areas.